Migraine: A Study of Nerve Blocks (Bupivacaine) vs Placebo for the Prevention of Migraine

Purpose

This is a prospective, randomized, double-blinded study that will be performed at Barrow Neurological Institute in the Jan and Tom Lewis Migraine Treatment Program. This study will enroll patients who are naïve to nerve blocks who are planning on receiving nerve blocks as their standard of care treatment. The study will require participants to keep a daily migraine calendar which will be provided at the screening visit. Participants who qualify for the study will receive one nerve block or placebo treatment and be followed up with daily migraine charting and monthly questionnaires for 3 months. Primary endpoint of this study is monthly migraine days at one month after nerve blocks compared to baseline.